Genetic protection of repopulating hematopoietic cells with an improved MDR1-retrovirus allows administration of intensified chemotherapy following stem cell transplantation in mice

International Journal of Cancer

Volumn 98, Issue 5, 2002, Pages 785-792

  Carpinteiro, Alexander ^a   Peinert, Stefan ^a   Ostertag, Wolfram ^a   Zander, Axel R ^b   Hossfeld, Dieter K ^b   Kühlcke, Klaus ^c   Eckert, Hans Georg ^c   Baum, Christopher ^a,b,d   Hegewisch Becker, Susanna ^b  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c BIONTECH AG   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Bone marrow transplantation; Chemotherapy; Gene therapy; Multidrug resistance

Indexed keywords

ANTINEOPLASTIC AGENT; COLCHICINE; FLUOROCHROME; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; RHODAMINE 123; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; BONE MARROW CELL; BONE MARROW TOXICITY; CELL CULTURE; CELL POPULATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; STEM CELL TRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD CELL COUNT; COLONY-FORMING UNITS ASSAY; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, MDR; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MICE, INBRED C57BL; PACLITAXEL; RETROVIRIDAE;

EID: 0037051675     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10206     Document Type: Article

References (49)

1. Much ado about not enough data: High-dose chemotherapy with autologous stem cell rescue for breast cancer
2. Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologons bone marrow transplantation
3. Oxygen delivery: Implications for the biology and therapy of solid tumors
4. Hypoxic cervical cancers with low apoptotic index are highly aggressive
5. Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma
6. Transfer of drug resistance genes into hematopoietic progenitors
7. Therapeutic strategies involving the multidrug resistance phenotype: The MDR1 gene as target, chemoprotectant and selectable marker in gene therapy
8. Chemotherapy and chemo-sensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: Efficacy, potency and toxicity
9. Rhodamine-123 staining in hematopoietic stem cells of young mice indicates mitochondrial activation rather than dye efflux
10. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1
11. Transfer and expression of the human multiple drug resistance gene into live mice
12. Resistance to taxol chemotherapy produced in mouse marrow-cells by safety-modified retroviruses containing a human mdr-1 transcription unit
13. Transduction of MDR1 into human and mouse haemopoietic progenitor cells: Use of rhodamine (Rh123) to determine transduction frequency and in vivo selection
14. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer
15. Feasibility of multidrug resistance (MDR-1) gene transfer in patients undergoing high-dose therapy and peripheral blood stem cell transplantation for lymphoma
16. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation
17. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells
18. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients
19. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy
20. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells
21. Bicistronic retroviral vectors for combining myeloprotection with cell surface marking
22. Evidence of both ontogeny and transplant dose-regulated expansion of hematopoietic stem cells in vivo
23. Frequency analysis of multidrug resistance-1 gene transfer into human primitive hematopoietic progenitor cells using the cobblestone area-forming cell assay and detection of vector-mediated P-glycoprotein expression by rhodamine-123
24. High-dose multidrug resistance in primary human hematopoietic progenitor cells transduced with optimized retroviral vectors
25. Quantitative assessment of retroviral gene transfer of the human multidrug resistance-1 gene to human mobilized peripheral blood progenitor cells engrafting in NOD/SCID mice
26. Cancer dormancy: Opportunities for new therapeutic approaches
27. High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors
28. Cytokine prestimulation as a gene therapy strategy: Implications for using the MDR1 gene as a dominant selectable marker
29. Dose-dense therapy with weekly 1-hour Paclitaxel infusions in the treatment of metastatic breast cancer
30. Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand and megakaryocyte growth and development factor
31. Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning
32. Efficient retroviral-mediated gene transfer to human cord blood stem cells with in vivo repopulating potential
33. High efficiency gene transfer to human hematopoietic SCID-repopulating cells under serum-free conditions
34. Dose-dependent transduction of vesicular stomatitis virus G protein-pseudotyped retrovirus vector into human solid tumour cell lines and murine fibroblasts
35. Influence of multiplicity of infection and protein stability on retroviral vector-mediated gene expression in hematopoietic cells
36. Expression of retroviral vectors containing the human multidrug resistance 1 cDNA in hematopoietic cells of transplanted mice
37. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors
38. Design of 5′ untranslated sequences in retroviral vectors developed for medical use
39. The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction
40. What we have learned from retroviral marking of hematopoietic stem cells
41. Retroviral-mediated MDR1 gene transfer into NOD/SCID repopulating hematopoietic cells under clinically relevant conditions
42. Improved post-transcriptional processing of an MDR1-retrovirus elevates expression of multidrug resistance in primary human hematopoietic cells
43. Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice
44. The effect of multidrug-resistance 1 gene versus neo transduction on ex vivo and in vivo expansion of rhesus macaque hematopoietic repopulating cells
45. In vivo selection of retrovirally transduced hematopoietic stem cells
46. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells